Seridopidine

Seridopidine
Clinical data
Other namesACR343; ACR-343
Routes of
administration		Oral
Drug classDopamine D2 receptor modulator
ATC code
  • None
Identifiers
  • 1-ethyl-4-(3-fluoro-5-methylsulfonylphenyl)piperidine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H20FNO2S
Molar mass285.38 g·mol−1
3D model (JSmol)
  • CCN1CCC(CC1)C2=CC(=CC(=C2)S(=O)(=O)C)F
  • InChI=1S/C14H20FNO2S/c1-3-16-6-4-11(5-7-16)12-8-13(15)10-14(9-12)19(2,17)18/h8-11H,3-7H2,1-2H3
  • Key:PHRDGRSMZPOCAB-UHFFFAOYSA-N

Seridopidine (INNTooltip International Nonproprietary Name; developmental code name ACR343) is a dopamine D2 receptor modulator and so-called "dopaminergic stabilizer" which is or was under development for the treatment of Parkinson's disease and Tourette's syndrome. It is taken orally. The drug is or was under development by Carlsson Research AB, NeuroSearch, and Saniona. As of June 2019, no recent development has been reported for Parkinson's disease or Tourette's syndrome. The drug has reached phase 1 clinical trials for both indications. It entered phase 1 trials by 2008. Seridopidine is one of the "dopidine" drugs, with the others including pridopidine (ACR-16) and ordopidine (ACR-325).

See also

References

  1. 1 2 3 4 5 6 "Seridopidine". AdisInsight. 28 June 2019. Retrieved 1 June 2026.
  2. 1 2 Ellis JM, Fell MJ (September 2017). "Current approaches to the treatment of Parkinson's Disease". Bioorganic & Medicinal Chemistry Letters. 27 (18): 4247–4255. doi:10.1016/j.bmcl.2017.07.075. PMID 28869077. The most active area of clinical research for symptomatic treatment of PD remains direct and indirect dopamine modulation. ACR 325 (orotidine, completed Phase 1,16 structure unreported) and ACR343 (seridopidine, structure unreported) are dopamine stabilizers (D2 modulators) that were transferred in September 2016 to Saniona AB as Phase 2 ready for a PD trial.17 Neurosearch led the early discovery efforts that originated these molecules, which are structural analogs of another Neurosearch dopamine stabilizer, pridopidine (22). Pridopidine (22) was licensed by Teva in 2012 and completed two Phase 3 Huntington Disease (HD) trials.18 The FDA and EMA have assessed pridopidine (22) as unapprovable for HD based on the two existing Phase 3 trials, and it is unclear what impact this collection of D2 modulators may have in PD (Fig. 8).
  3. 1 2 3 Sommer DB, Stacy MA (December 2008). "What's in the pipeline for the treatment of Parkinson's disease?". Expert Review of Neurotherapeutics. 8 (12): 1829–1839. doi:10.1586/14737175.8.12.1829. PMID 19086879. NeuroSearch has also reported the launch of a Phase I clinical trial of ACR343, a dopaminergic stabilizer, as a treatment for dyskinesias, but no information about ACR343 is available [216].
  4. 1 2 Waters SH (2015). Comparative in vivo pharmacology of dopidines A novel class of compounds discovered by phenotypic screening (Ph.D. thesis). Göteborgs Universiteit. Retrieved 1 June 2026.